ID   CMK
AC   CVCL_0216
DR   BTO; BTO:0000978
DR   CLO; CLO_0002526
DR   EFO; EFO_0003037
DR   MCCL; MCC:0000105
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473574
DR   BioSample; SAMN10988101
DR   CCLE; CMK_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM00959
DR   ChEMBL-Cells; CHEMBL3308149
DR   ChEMBL-Targets; CHEMBL2366177
DR   Cosmic; 787423
DR   Cosmic; 910566
DR   Cosmic; 919131
DR   Cosmic; 975241
DR   Cosmic; 1012061
DR   Cosmic; 1070695
DR   Cosmic; 1176598
DR   Cosmic; 1191081
DR   Cosmic; 1191702
DR   Cosmic; 1281307
DR   Cosmic; 1286955
DR   Cosmic; 1315742
DR   Cosmic; 1524829
DR   Cosmic; 1559970
DR   Cosmic; 2089668
DR   Cosmic; 2131535
DR   Cosmic; 2306202
DR   Cosmic-CLP; 910566
DR   DepMap; ACH-000641
DR   DSMZ; ACC-392
DR   ENCODE; ENCBS071ENC
DR   GDSC; 910566
DR   GEO; GSM236781
DR   GEO; GSM236817
DR   GEO; GSM510583
DR   GEO; GSM886938
DR   GEO; GSM888005
DR   GEO; GSM1374449
DR   IARC_TP53; 21228
DR   LiGeA; CCLE_184
DR   LINCS_LDP; LCL-1051
DR   PharmacoDB; CMK_210_2019
DR   Progenetix; CVCL_0216
DR   TOKU-E; 4113
DR   Wikidata; Q54813770
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1571549;
RX   PubMed=1991165;
RX   PubMed=2217443;
RX   PubMed=2527057;
RX   PubMed=2665839;
RX   PubMed=8784480;
RX   PubMed=9510473;
RX   PubMed=9738977;
RX   PubMed=10674912;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=23325432;
RX   PubMed=23955599;
RX   PubMed=27397505;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/CMK_Stam_protocol.pdf
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Doubling time: ~40 hours (PubMed=2527057); ~40-50 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
CC   Sequence variation: Gene fusion; HGNC; 4024; FXR2 + HGNC; 11998; TP53; Name(s)=TP53-FXR2 (from child cell lines & inference from Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.58%; Native American=0%; East Asian, North=93.95%; East Asian, South=3.14%; South Asian=0%; European, North=0%; European, South=2.33% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 11
ST   D16S539: 9,11
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   TH01: 7
ST   TPOX: 9,11
ST   vWA: 18
DI   NCIt; C2993; Down syndrome
DI   NCIt; C43223; Myeloid leukemia associated with Down syndrome
DI   ORDO; Orphanet_870; Down syndrome
DI   ORDO; Orphanet_99887; Acute megakaryoblastic leukemia in Down syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   10M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 34
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1571549; DOI=10.1182/blood.V79.9.2378.2378;
RA   Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K.,
RA   Ishikawa F., Takaku F., Yazaki Y., Hirai H.;
RT   "Frequent mutations in the p53 gene in human myeloid leukemia cell
RT   lines.";
RL   Blood 79:2378-2383(1992).
//
RX   PubMed=1991165; DOI=10.1182/blood.V77.3.481.481;
RA   Sakaguchi M., Sato T., Groopman J.E.;
RT   "Human immunodeficiency virus infection of megakaryocytic cells.";
RL   Blood 77:481-485(1991).
//
RX   PubMed=2217443;
RA   Miura Y., Komatsu N., Suda T.;
RT   "Growth and differentiation of two human megakaryoblastic cell lines;
RT   CMK and UT-7.";
RL   Prog. Clin. Biol. Res. 356:259-270(1990).
//
RX   PubMed=2527057; DOI=10.1111/j.1365-2141.1989.tb07681.x;
RA   Sato T., Fuse A., Eguchi M., Hayashi Y., Ryo R., Adachi M.,
RA   Kishimoto Y., Teramura M., Mizoguchi H., Shima Y., Komori I.,
RA   Sunami S., Okimoto Y., Nakajima H.;
RT   "Establishment of a human leukaemic cell line (CMK) with
RT   megakaryocytic characteristics from a Down's syndrome patient with
RT   acute megakaryoblastic leukaemia.";
RL   Br. J. Haematol. 72:184-190(1989).
//
RX   PubMed=2665839; DOI=10.1182/blood.V74.1.42.42;
RA   Komatsu N., Suda T., Moroi M., Tokuyama N., Sakata Y., Okada M.,
RA   Nishida T., Hirai Y., Sato T., Fuse A., Miura Y.;
RT   "Growth and differentiation of a human megakaryoblastic cell line,
RT   CMK.";
RL   Blood 74:42-48(1989).
//
RX   PubMed=8784480; DOI=10.1159/000227600;
RA   Shinohara A., Shimizu E., Takada M., Sone S.;
RT   "Lack of c-mpl proto-oncogene transcripts and growth-stimulatory
RT   effects of thrombopoietin on human small cell lung cancer cell
RT   lines.";
RL   Oncology 53:426-434(1996).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=10674912; DOI=10.3109/10428190009148861;
RA   Sato T., Sekine H., Kakuda H., Miura N., Sunohara M., Fuse A.;
RT   "HIV infection of megakaryocytic cell lines.";
RL   Leuk. Lymphoma 36:397-404(2000).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//